{"id":414897,"date":"2021-01-14T08:33:33","date_gmt":"2021-01-14T13:33:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=414897"},"modified":"2021-01-14T08:33:33","modified_gmt":"2021-01-14T13:33:33","slug":"pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/","title":{"rendered":"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology"},"content":{"rendered":"

\nPromotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment
\n<\/h2>\n
\n

FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology, today released a white paper detailing how the Versamune\u00ae platform works to treat cancer, and the potential of Versamune\u00ae in the treatment of a broad range of cancers.<\/p>\n

Cancer immunotherapy is a form of cancer treatment that utilizes the power of the body\u2019s own immune system to recognize, attack and eliminate cancer. The goal of cancer immunotherapy is tumor eradication and regression or, at least, disease stabilization. Cancer immunotherapies have significant potential to treat a broad range of cancers, and multiple agents have been approved by the FDA to treat a wide range of cancers at various stages. Though progress has been made in developing new anti-cancer immunotherapeutic technologies and products, significant challenges limiting their clinical effectiveness and safety remain.<\/p>\n

There are well recognized hurdles impeding the ability of immunotherapy to harness the body\u2019s immune system most effectively. For example, approved checkpoint inhibitors have resulted in effective, durable responses. Unfortunately, the rates of response reported are only in the range of 15-20% and are most likely to occur in patients with evidence of a pre-existing immune response to their tumor. Furthermore, immune therapies, including checkpoint inhibitors, CAR-Ts and live-vector vaccines, may cause significant systemic toxicities limiting their use either in the early-stage cancer setting or in combination with other approved anti-cancer treatments.<\/p>\n

A significant challenge in the development of an effective cancer immunotherapy is creating a simple and easy to administer therapy that can promote the induction of highly potent, targeted, tumor-specific CD8+ killer and CD4+ helper T-cells within patients, that will effectively treat their cancer with minimal side effects. There is scientific consensus that induction of an adequate number and potency of tumor-recognizing T-cells is necessary for effective immunotherapy. However, suboptimal T-cell activation remains a key limitation of many immunotherapies.<\/p>\n

In two recent peer reviewed articles in the Journal of Immunology<\/em> and the Journal for Immunotherapy of Cancer <\/em>(available on the company\u2019s website), Versamune\u00ae-based immunotherapies were shown to induce superior quantity and quality of tumor-recognizing killer T-cells in-vivo<\/em>. This resulted in superior preclinical anti-tumor efficacy. Versamune\u00ae\u2019s ability to be combined with specific proteins found primarily on the tumor cells and its ability to induce an effective anti-tumor immune response specific to the protein and cancer, offers opportunities to treat a variety of cancers. Further, its diverse mechanisms of action and favorable safety profile suggest therapeutic promise when used alone in the single-agent monotherapy setting or when used in combination with standard of care therapies such as checkpoint inhibitors as well as chemo and radiation therapy to enhance the efficacy of treatment.<\/p>\n

The current PDS Biotech pipeline of Versamune\u00ae-based therapies focuses on four key antigens associated with a broad variety of solid tumors that remain challenging to treat. According to PDS Biotech CEO, Dr. Frank Bedu-Addo, “We are currently pursuing an ambitious development strategy, working with leading oncology experts to assess the potential of Versamune\u00ae to bring new and improved treatments to cancer patients.\u201d<\/p>\n

Read Versamune\u00ae: A New Generation of Cancer Immunotherapies<\/em>here<\/a>.<\/p>\n

\n About PDS Biotechnology<\/strong>\n <\/p>\n

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology platform. The company\u2019s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in multiple indications. Versamune\u00ae effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has developed multiple therapies, based on combinations of Versamune\u00ae and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com<\/a> or follow us on Twitter at @PDSBiotech.<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the \u201cCompany\u201d) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company\u2019s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201clikely,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cforecast.\u201d \u201cguidance\u201d, \u201coutlook\u201d and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company\u2019s ability to protect its intellectual property rights; the Company\u2019s anticipated capital requirements, including the Company\u2019s anticipated cash runway and the Company\u2019s current expectations regarding its plans for future equity financings; the Company\u2019s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company\u2019s operations or require the Company to relinquish rights to the Company\u2019s technologies or product candidates; the Company\u2019s limited operating history in the Company\u2019s current line of business, which makes it difficult to evaluate the Company\u2019s prospects, the Company\u2019s business plan or the likelihood of the Company\u2019s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101; the future success of such trials; the successful implementation of the Company\u2019s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company\u2019s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company\u2019s product candidates; the acceptance by the market of the Company\u2019s product candidates, if approved; the timing of and the Company\u2019s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company\u2019s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company\u2019s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company\u2019s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n Media & Investor Relations Contact:<\/strong>\n <\/p>\n

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com<\/a><\/p>\n

Jacob Goldberger
CG Capital
Phone: +1 (404) 736-3841
Email: jacob@cg.capital<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology, today released a white paper detailing how the Versamune\u00ae platform works to treat cancer, and the potential of Versamune\u00ae in the treatment of a broad range of cancers. Cancer immunotherapy is a form of cancer treatment that utilizes the power of the body\u2019s own immune system to recognize, attack and eliminate cancer. The goal of cancer immunotherapy is tumor eradication and regression or, at least, disease stabilization. Cancer immunotherapies have significant potential to treat a broad … <\/p>\n

Continue reading “PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-414897","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology, today released a white paper detailing how the Versamune\u00ae platform works to treat cancer, and the potential of Versamune\u00ae in the treatment of a broad range of cancers. Cancer immunotherapy is a form of cancer treatment that utilizes the power of the body\u2019s own immune system to recognize, attack and eliminate cancer. The goal of cancer immunotherapy is tumor eradication and regression or, at least, disease stabilization. Cancer immunotherapies have significant potential to treat a broad … Continue reading "PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-14T13:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology\",\"datePublished\":\"2021-01-14T13:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/\"},\"wordCount\":1278,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/\",\"name\":\"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=\",\"datePublished\":\"2021-01-14T13:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/","og_locale":"en_US","og_type":"article","og_title":"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology - Market Newsdesk","og_description":"Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology, today released a white paper detailing how the Versamune\u00ae platform works to treat cancer, and the potential of Versamune\u00ae in the treatment of a broad range of cancers. Cancer immunotherapy is a form of cancer treatment that utilizes the power of the body\u2019s own immune system to recognize, attack and eliminate cancer. The goal of cancer immunotherapy is tumor eradication and regression or, at least, disease stabilization. Cancer immunotherapies have significant potential to treat a broad … Continue reading \"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-14T13:33:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology","datePublished":"2021-01-14T13:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/"},"wordCount":1278,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/","name":"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=","datePublished":"2021-01-14T13:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTY3NCMzOTE4NjI2IzIwMTcxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-overcoming-a-major-limitation-of-immuno-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PDS Biotech Releases White Paper Detailing the Potential of the Versamune\u00ae Platform in Overcoming a Major Limitation of Immuno-Oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=414897"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414897\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=414897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=414897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=414897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}